Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease

Patients with steroid-refractory acute graft-versus-host disease (aGVHD) have a high mortality due to infections and progressive aGVHD. We investigated the combined use of 2 monoclonal antibodies (Mabs), daclizumab and infliximab in steroid-refractory aGVHD to selectively control the proliferation o